NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Insider

LENZ

LENZ Therapeutics Inc

Jul 01 • 04:00PM ET

30.05

Dollar change +0.74
Percentage change 2.52	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BMY GILD REGN VRTX BIIB NBIX ALNY BMRN IONS

| Held by: VTI IWM VXF IWO IBB SCHA VTWO XPH IWC VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.77	Insider Own	20.89%	Shs Outstand	27.54M	Perf Week	0.91%
Market Cap	845.79M	Forward P/E	-	EPS next Y	-2.73	Insider Trans	-10.43%	Shs Float	22.27M	Perf Month	2.91%
Enterprise Value	652.88M	PEG	-	EPS next Q	-0.64	Inst Own	81.35%	Short Float	15.27%	Perf Quarter	16.88%
Income	-47.74M	P/S	-	EPS this Y	-22.62%	Inst Trans	4.93%	Short Ratio	11.90	Perf Half Y	-6.12%
Sales	0.00M	P/B	4.31	EPS next Y	4.83%	ROA	-22.81%	Short Interest	3.40M	Perf YTD	4.09%
Book/sh	6.97	P/C	4.36	EPS next 5Y	31.34%	ROE	-24.47%	52W High	38.93 -22.81%	Perf Year	68.73%
Cash/sh	6.90	P/FCF	-	EPS past 3/5Y	35.06% -181.63%	ROIC	-24.78%	52W Low	16.53 81.74%	Perf 3Y	125.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.54% 6.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	88.86%	Oper. Margin	-	ATR (14)	1.90	Perf 10Y	-
Dividend Ex-Date	Mar 15, 2024	Quick Ratio	23.09	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.90	Recom	1.12
Dividend Gr. 3/5Y	- -	Current Ratio	23.09	EPS Q/Q	84.95%	SMA20	0.79%	Beta	0.51	Target Price	44.38
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	5.08%	Rel Volume	0.87	Prev Close	29.31
Employees	42	LT Debt/Eq	0.00	Earnings	May 07 AMC	SMA200	10.67%	Avg Volume	285.70K	Price	30.05
IPO	Jun 25, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.26% -	Trades		Volume	249,914	Change	2.52%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-14-25	Resumed	Piper Sandler	Overweight	$38 → $51
Mar-18-25	Initiated	TD Cowen	Buy	$60
Sep-27-24	Initiated	Raymond James	Outperform	$37
Aug-12-24	Initiated	H.C. Wainwright	Buy	$38
Apr-15-24	Initiated	William Blair	Outperform
Apr-15-24	Initiated	Leerink Partners	Outperform	$32
Apr-10-24	Initiated	Citigroup	Buy	$34
Mar-27-24	Initiated	Piper Sandler	Overweight	$28
Feb-23-23	Downgrade	Cowen	Outperform → Market Perform
Feb-23-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$3
Feb-23-23	Downgrade	BofA Securities	Neutral → Underperform	$3 → $2
Jan-25-23	Downgrade	BTIG Research	Buy → Neutral
Jan-18-23	Downgrade	BofA Securities	Buy → Neutral	$7 → $3
Jan-06-23	Downgrade	SVB Leerink	Outperform → Mkt Perform	$11 → $2
Jan-06-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$14 → $7
Sep-15-22	Initiated	Cantor Fitzgerald	Overweight	$12
Jun-17-22	Initiated	BMO Capital Markets	Outperform	$12
Apr-14-22	Initiated	BTIG Research	Buy	$18
Mar-22-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19 → $8
Feb-18-22	Initiated	RBC Capital Mkts	Sector Perform	$11

Show Previous Ratings

May-27-25 08:00AM	LENZ Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
May-09-25 09:03AM	LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia (GlobeNewswire)
May-07-25 04:05PM	LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
May-06-25 04:30PM	LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference (GlobeNewswire) -11.03%
Apr-30-25 04:30PM	LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025 (GlobeNewswire) +7.08%
08:00AM	Loading…
Apr-07-25 08:00AM	LENZ Therapeutics: Freedom From Reading Glasses (Seeking Alpha) -7.93%
Apr-01-25 07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
Mar-27-25 05:33PM	LENZ Therapeutics Stock Is Attractive Before PDUFA (SeekingAlpha)
Mar-19-25 08:09PM	Lenz Therapeutics outlines Q4 2025 launch plans for LNZ100 amid FDA review progress (SeekingAlpha)
08:09PM	LENZ Therapeutics, Inc. (LENZ) Q4 2024 Earnings Call Transcript (SeekingAlpha)
04:05PM	LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-11-25 08:00AM	LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025 (GlobeNewswire)
Mar-03-25 08:00AM	LENZ Therapeutics to Host Commercial Day on April 15, 2025 (GlobeNewswire)
Feb-24-25 08:00AM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 08:00AM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Nov-06-24 07:00AM	LENZ Therapeutics Reports Third Quarter 2024 Financial Results (GlobeNewswire) +12.50%
Oct-30-24 08:00AM	LENZ Therapeutics to Report Third Quarter Financial Results and Business Update on November 6, 2024 (GlobeNewswire)
Oct-27-24 09:00PM	CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100 (GlobeNewswire)
Oct-22-24 08:10AM	Lenz Therapeutics announces FDA acceptance of NDA for LNZ100 (TipRanks) -9.27%
Oct-21-24 08:00AM	LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia (GlobeNewswire)
Sep-30-24 08:00AM	LENZ Therapeutics Announces Presentations at Upcoming Ophthalmology and Optometry Medical Conferences (GlobeNewswire)
Aug-27-24 04:01PM	LENZ Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-24 04:05PM	LENZ Therapeutics Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 08:00AM	LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia (GlobeNewswire)
Aug-07-24 04:01PM	LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024 (GlobeNewswire)
Jul-15-24 08:00AM	LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital (GlobeNewswire)
Jun-10-24 08:00AM	LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024 (GlobeNewswire) +14.18%
May-30-24 08:00AM	LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-24 09:03AM	LENZ Therapeutics, Inc. (NASDAQ:LENZ) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:01PM	LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
04:01PM	Loading…
May-01-24 04:01PM	LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024 (GlobeNewswire)
Apr-03-24 07:00AM	LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials (Business Wire)
Apr-02-24 04:01PM	LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials (Business Wire)
Mar-21-24 04:30PM	LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress (Business Wire) +7.64%
10:09AM	11 Stocks that Paid Special Dividends in 2024 (Insider Monkey)
Mar-08-24 05:00PM	Graphite Bio Declares Special Dividend In Connection with Proposed Merger with Lenz Therapeutics (Business Wire) +18.79%
Mar-01-24 10:48AM	Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Feb-02-24 11:58AM	Kuehn Law Encourages DSKE, RYZB, ROVR, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:07PM	SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FNCB, PWFL, DOC, GRPH (GlobeNewswire)
Nov-16-23 12:00PM	What Makes Graphite Bio, Inc. (GRPH) a New Buy Stock (Zacks)
Nov-15-23 07:00AM	LENZ Therapeutics and Graphite Bio Announce Merger Agreement (Business Wire)
Jun-23-23 07:00AM	Graphite Bio Announces Departure of Chief Financial Officer (Business Wire)
May-15-23 07:44AM	Graphite Bio, Inc.'s (NASDAQ:GRPH) largest shareholders are private equity firms with 43% ownership, institutions own 22% (Simply Wall St.) +6.02%
May-10-23 10:18AM	Should You Buy Graphite Bio (GRPH) Ahead of Earnings? (Zacks)
Apr-26-23 02:10PM	12 Gene Editing Stocks With the Best Long-Term Potential (Insider Monkey)
Mar-29-23 04:20PM	11 Most Promising Gene Editing Stocks According to Analysts (Insider Monkey)
Mar-25-23 10:12AM	We're Keeping An Eye On Graphite Bio's (NASDAQ:GRPH) Cash Burn Rate (Simply Wall St.)
Mar-20-23 04:05PM	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2022 Financial Results (Business Wire)
Feb-23-23 05:36PM	Sickle-cell gene therapy developer stops program, cuts half of staff (American City Business Journals) +15.91%
Feb-22-23 04:05PM	Graphite Bio Announces Process to Explore Strategic Alternatives and Corporate Restructuring (Business Wire)
Jan-10-23 09:35AM	Down -39.59% in 4 Weeks, Here's Why Graphite Bio, Inc. (GRPH) Looks Ripe for a Turnaround (Zacks)
Jan-06-23 05:54PM	Two Covid-era biotech IPOs Spruce and Graphite Bio see stock head in different directions (American City Business Journals) -39.54%
09:07AM	Graphite Bio Shares Tank After Pausing Sickle Cell Therapy Study (Benzinga)
Jan-05-23 05:57PM	Graphite Bio pauses early-stage blood disease therapy trial (Reuters)
04:05PM	Graphite Bio Announces Voluntary Pause of Phase 1/2 CEDAR Study of nulabeglogene autogedtemcel (nula-cel) for Sickle Cell Disease (Business Wire)
Dec-11-22 10:00AM	Graphite Bio Presents Preclinical Data for Novel Sequencing Method Used to Determine Gene Editing Outcomes at 64th ASH Annual Meeting (Business Wire)
Nov-21-22 08:00AM	Graphite Bio Announces Participation in Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-17-22 09:45AM	2 Strong Buy Penny Stocks That Could See 200% Gains (Or More) (TipRanks)
Nov-09-22 04:05PM	Graphite Bio Reports Recent Business Progress and Third Quarter 2022 Financial Results (Business Wire)
Nov-03-22 09:05AM	Graphite Bio Announces Abstracts Accepted for Upcoming 64th ASH Annual Meeting and Exposition (Business Wire)
Oct-16-22 08:33AM	Here's Why We're Watching Graphite Bio's (NASDAQ:GRPH) Cash Burn Situation (Simply Wall St.)
Oct-11-22 08:00AM	Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention (Business Wire)
Sep-06-22 08:00AM	Graphite Bio Announces Participation in Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire)
Aug-30-22 05:47PM	Potential sickle cell disease 'cure' jumps to clinic, yet investors remain cool (American City Business Journals)
Aug-11-22 04:05PM	Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results (Business Wire) +5.03%
08:16AM	Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease (Business Wire)
Jun-17-22 02:26PM	BMO Capital Sees Over 400% Upside For This Small Gene-Editing Stock (Benzinga) +12.15%
Jun-01-22 08:00AM	Graphite Bio Announces Participation in Jefferies Healthcare Conference (Business Wire)
May-29-22 02:15PM	I'm 'Following Up' on a Biotech Trade With Attractive Potential (TheStreet.com)
May-16-22 06:00AM	Graphite Bio Presents Preclinical Gene Replacement Data for GPH102 for Beta-thalassemia at the ASGCT 25th Annual Meeting (Business Wire)
May-12-22 04:05PM	Graphite Bio Reports Recent Business Progress and First Quarter 2022 Financial Results (Business Wire) +14.04%
May-09-22 08:13AM	Graphite Bio (NASDAQ:GRPH) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.) -19.44%
May-04-22 08:00AM	Graphite Bio Announces Participation in Upcoming Investor Conferences (Business Wire) +6.22%
May-03-22 08:00AM	Graphite Bio Announces U.S. FDA Fast Track Designation Granted to GPH101 for the Treatment of Sickle Cell Disease (Business Wire)
May-02-22 04:38PM	Graphite Bio Announces Participation in the ASGCT 25th Annual Meeting Including Oral Presentation About Beta-thalassemia Program (Business Wire)
Mar-28-22 08:00AM	Graphite Bio Announces Participation in H.C. Wainwright Gene Therapy and Gene Editing Virtual Conference (Business Wire)
Mar-23-22 12:28PM	Insiders who purchased Graphite Bio, Inc. (NASDAQ:GRPH) earlier this year lose an additional US$64k as the stock sinks to US$6.16 (Simply Wall St.) -8.60%
08:00AM	Graphite Bio Announces Formation of Scientific Advisory Board (Business Wire)
Mar-21-22 08:25AM	Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results (Business Wire) -15.15%
Mar-03-22 08:00AM	Graphite Bio Announces Participation in Upcoming Cowen 42nd Annual Health Care Conference (Business Wire)
Mar-02-22 08:00AM	Graphite Bio Appoints Alethia Young as Chief Financial Officer (Business Wire)
Feb-08-22 10:20AM	Is a Surprise Coming for Graphite Bio (GRPH) This Earnings Season? (Zacks)
Jan-27-22 08:00AM	Graphite Bio Announces Participation in Upcoming Investor Conferences (Business Wire) -6.67%
Jan-26-22 06:30PM	Expanding gene editing firm Graphite Bio signs new lease in South San Francisco (American City Business Journals)
Dec-11-21 09:00AM	Graphite Bio Presents Overview of Phase 1/2 CEDAR Trial Evaluating Investigational Gene Editing Therapy GPH101 in Sickle Cell Disease at 63rd ASH Annual Meeting and Exposition (Business Wire)
Dec-07-21 08:00AM	Graphite Bio to Host Key Opinion Leader Webinar on Gene Correction for Sickle Cell Disease (Business Wire) +5.94%
Nov-17-21 08:00AM	Graphite Bio Enrolls First Patient in Phase 1/2 Clinical Trial of GPH101 for Sickle Cell Disease (Business Wire)
Nov-10-21 04:05PM	Graphite Bio Reports Recent Business Progress and Third Quarter 2021 Financial Results (Business Wire)
Nov-04-21 09:13AM	Graphite Bio Announces Presentation on Phase 1/2 CEDAR Trial of GPH101 in Sickle Cell Disease at Upcoming 63rd ASH Annual Meeting and Exposition (Business Wire)
Oct-21-21 08:00AM	Graphite Bio Announces Participation in Upcoming Jefferies Gene Therapy/Editing Summit (Business Wire)
Oct-18-21 11:00AM	10% Owner Of Graphite Bio Makes $670K Buy (Benzinga)
04:37AM	3 Stocks Insiders Are Buying (Benzinga)
Oct-12-21 01:00PM	Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention (Business Wire)
Oct-05-21 08:00AM	Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention (Business Wire) -6.79%
Sep-25-21 10:12AM	We Think Graphite Bio (NASDAQ:GRPH) Can Afford To Drive Business Growth (Simply Wall St.)
Aug-30-21 08:00AM	Graphite Bio Announces Participation in Upcoming September Investor Conferences (Business Wire)
Aug-12-21 04:05PM	Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results (Business Wire)
Jun-30-21 05:15PM	Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares (Business Wire) +11.34% -8.07%
Jun-24-21 09:08PM	Graphite Bio Announces Pricing of Upsized Initial Public Offering (Business Wire)

LENZ Therapeutics, Inc. is a pre-commercial biopharmaceutical company, which focuses on the development and commercialization of innovative therapies to improve vision. It offers eye drop product treatment for presbyopia. The company was founded by James W. McCollum in July 2013 and is headquartered in Solana Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Versant Venture Capital VI, L.	10% Owner	Jun 20 '25	Sale	30.25	133,924	4,051,201	1,967,275	Jun 20 05:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 20 '25	Sale	30.35	100,877	3,061,617	1,047,912	Jun 20 05:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 18 '25	Sale	29.95	100,000	2,995,000	1,148,789	Jun 20 05:50 PM
Versant Venture Capital VI, L.	10% Owner	Jun 10 '25	Sale	29.00	350,000	10,150,000	1,248,789	Jun 12 04:37 PM
Olsson Shawn	Chief Commercial Officer	Apr 09 '25	Option Exercise	2.08	1,400	2,912	4,733	Apr 09 07:20 PM
Schimmelpennink Evert B.	President, CEO and Secretary	Mar 07 '25	Option Exercise	1.04	4,200	4,368	49,200	Mar 07 06:10 PM
Olsson Shawn	Chief Commercial Officer	Dec 16 '24	Option Exercise	2.08	3,333	6,933	3,333	Dec 17 07:55 PM
Schimmelpennink Evert B.	President, CEO and Secretary	Jul 22 '24	Option Exercise	1.04	45,000	46,800	45,000	Jul 23 08:16 PM

LENZ

LENZ Therapeutics Inc

Upgrade your FINVIZ experience